Daewoong Pharmaceutical "Diabetes New Drug Shows Efficacy and Safety in Phase 2 Clinical Trial"
[Asia Economy Reporter Cho Hyun-ui] Daewoong Pharmaceutical announced on the 21st that the efficacy and safety of 'Inavogliflozin,' a sodium-glucose co-transporter 2 (SGLT-2) inhibitor class diabetes treatment, were confirmed in a Phase 2 clinical trial.
In this clinical trial, Inavogliflozin was administered for 12 weeks to patients with type 2 diabetes whose blood sugar was not adequately controlled. From the 4th week, glycated hemoglobin (HbA1c) decreased compared to placebo, and at the 12th week, it decreased by about 0.9% compared to placebo.
Evaluating the treatment effect by subject at the 12th week, the proportion of patients who reached HbA1c of 7.0% or less reached up to 61%, showing an increase of more than 20% in the proportion of patients who responded compared to other companies' SGLT-2 inhibitors. The proportion of patients whose HbA1c decreased by more than 0.5% from baseline also recorded up to 72%, demonstrating excellent blood sugar reduction effects.
Additionally, genital and urethral infections, side effects that can occur due to the mechanism of SGLT-2 inhibitors, appeared at only about 2%, proving to be safer than other companies' drugs which accompany side effects at the 5-10% level.
Daewoong Pharmaceutical has completed the domestic Phase 2 clinical trial of Inavogliflozin and plans to enter Phase 3 clinical trials within the year to obtain approval for the treatment indication of type 2 diabetes. The company aims to launch domestically in 2023.
Hot Picks Today
Up to 600 Million Won for Semiconductors, 160 Million Won Bonus for Loss-Making Non-Memory… Samsung Electronics Labor and Management Reach Tentative Deal on Unprecedented Performance Compensation (Comprehensive)
- "Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- [Exclusive] 450 Billion Won Korean Investment at Risk as Canadian PE Moves to Acquire US Ascend for $99.2 Million
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Jeon Seung-ho, CEO of Daewoong Pharmaceutical, stated, "As the excellent efficacy and safety of Inavogliflozin have been proven through this Phase 2 clinical trial, we will accelerate efforts to create the best new drug within the SGLT-2 inhibitor class," adding, "We will also accelerate research and development targeting the global market through broad overseas partnerships."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
